Navigation Links
Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
Date:2/26/2013

tive expenses for the full year 2012 were $2.6 million, compared to $2.2 million for the full year 2011. This increase is related to professional fees and non-cash expenses for replacing previously issued warrants to Sigma-Tau upon reacquiring the rights to orBec® and accelerating the vesting of certain stock options issued to a former employee.

As of December 31, 2012, the Company's cash position was $3.4 million with working capital of $2.7 million.  

Christopher J. Schaber , PhD, President and Chief Executive Officer of Soligenix stated, "Throughout the year, we continued to make progress in advancing a number of our programs utilizing oral BDP, in both our BioTherapeutics and Vaccine/BioDefense business segments, as well as expanding our pipeline with acquired technology. In December 2012, we were successful in regaining North American and European commercial rights to oral BDP from Sigma-Tau and we expanded our pipeline with the acquisition of a novel innate defense regulator technology known as SGX94. We believe SGX94 is highly synergistic with our existing development pipeline in cancer supportive care and biodefense, and we anticipate the potential for a number of grant funding opportunities for SGX94 across both business segments."

Schaber continued, "In January, we were pleased to receive an invitation from the Biomedical Advanced Research and Development Authority (BARDA) to submit a contract proposal for the development of OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS), which was submitted in February.  We are also pleased with the momentum we have built entering 2013, and are excited about the opportunities we see in both of our business segments. I look forward to reporting on our progress on all programs throughout the coming year."

Soligenix's Recent Highlights:


    SOURCE Soligenix, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
    2. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
    3. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
    4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    9. Pharmasset Reports Fiscal Year End 2011 Financial Results
    10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
    (Date:12/17/2014)... Audacity, a leading California-based health and ... the Huntsworth Health Group, is proud to announce the ... her role, Gonzales will serve as Senior Vice President ... to welcome a talent of Jamie’s caliber to the ... “She is a proven healthcare innovation leader and brand ...
    (Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation ... executive promotions as well as changes to Martine ... Executive Promotions United Therapeutics announced the ... and Co-Chief Executive Officer and David Zaccardelli , ... In connection with these promotions, Dr. Rothblatt,s title will ...
    (Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
    Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
    ... clot-forming platelets every day, but there are times when ... diseases or during invasive surgery. Now, University of Pennsylvania ... bone marrow cells called megakaryocytes to quadruple the number ... student of pharmacology in Penn,s Perelman School of Medicine, ...
    ... Warwick Department of Physics has been awarded a prestigious ... "Creating Silicon Based Platforms for New Technologies". The initiative ... to "cooltronics", enabling zero-power electronics and could be key ... million Platform Grant from the Engineering and Physical Sciences ...
    ... At an atomic scale, the tiniest bridge of gold -- ... strongest, according to new research by engineers at the University ... the result of experiments probing the characteristics of atomic-scale necks ... a cantilever was pushed into a flat, gold surface. An ...
    Cached Biology Technology:Penn researchers show single drug and soft environment can increase platelet production 2Penn researchers show single drug and soft environment can increase platelet production 3Warwick wins $2.7 million research grant to help 'cooltronics' 2Narrowest bridges of gold are also the strongest, study finds 2
    (Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
    (Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
    (Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
    Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
    ... April issue of the Journal of the American ... eating plans; dietary quality among children; and relationships between ... Increased Risk of Eating Disorders , While vegetarians tend ... non-vegetarians to be overweight or obese, they may be ...
    ... the Richard King Trainee Award. This award was instituted last ... to encourage ABMG trainees in their careers and to foster ... year the editorial board will review all articles published in ... or corresponding author during that year. The manuscript felt to ...
    ... Being able to accurately predict how a given ... non-responsive tumors the burden of undergoing toxic and ultimately ... a patient,s cancer-causing genetic lesions are contributing to drug ... Researchers led by Professor Scott Lowe, Ph.D., ...
    Cached Biology News:News from the April 2009 Journal of the American Dietetic Association 2Jonathan Berg, M.D., Ph.D. awarded Richard King Trainee Award for Best in Genetics in Medicine 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 3CSHL team develops mouse models of leukemia that predict response to chemotherapy 4
    Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
    Mouse Serpin F1/PEDF MAb (Clone 199315)...
    Human CCL26/Eotaxin-3 MAb (Clone 115002)...
    Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
    Biology Products: